EVALUATION OF CARBAPENEM USE AMONG PATIENTS AT INTENSIVE CARE UNIT (ICU) IN SANA'A, YEMEN by Alyahawi, Ali et al.
 Original Research Article 
 
Evaluation of Carbapenem Use among Patients at Intensive Care Unit 
(ICU) in Sana'a, Yemen 
 
Abstract 
Background: Drug Utilization Evaluation (DUE) studies are designed to evaluate and 
improve the rational use of medications. In this study, DUEhas focused on drugs used in high 
risk patients such as critically ill cases. Carbapenems are beta-lactam type antibiotics with 
broad-spectrum of activity which cover Gram-positive, Gram-negative and anaerobic 
bacteria. The heavy use of carbapenems (imipenem or meropenm) could increase the risk of 
multi-drug resistant (MDR) pathogens.  
Methods: This study was a prospective and cross sectional study performed at intensive care 
unit (ICU) of Al-Matwakel hospital in Sana'a, Yemen. The study was conducted from 
September 2018 to March 2019. All of the patients were on imipenem or meropenem as an 
empiric treatment or based upon microbiology culture results included in the study.  
Results: Total of 80 patients at ICU were evaluated. The results of the study showed that 
empiric therapy was in most cases (91.25%; P < 0.001).In addition; about 36.3% of the 
patients required dosage adjustment according to glomerular filtration rate(GFR) stages. Also 
according to GFR calculation, 43.8% of the patients were in stage 3. In the present study, the 
frequency of therapeutic duplication of ceftriaxone with carbapenem was reported in 38 
patients. The major drug-drug interactions were observed with tramadol-imipenem, tramadol-
meropenem, and amlodipine-simvastatin  
Conclusion: The result of the study showed that empiric therapy was unjustified in most 
cases (91.25%).In addition, about 36.3% of the patients required dosage adjustment 
according to GFR stages. According to GFR calculation, 43.8% of the patients were in stage 
3. In the present study, the frequency of therapeutic duplication and drug-drug interactions 
were observed. 
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1. Introduction: 
One of the most important elements in patient care process is to evaluate the appropriateness 
of medication use. Medications review studies are aimed to evaluate and improve the rational 
use of drugs. They have mostly focused on drugs with higher cost, higher dispensing, 
relatively narrow therapeutic margin and also broad spectrum antibiotics. They also focus on 
medicationsprescribed in specialized populations such as elderly, critically ill, post-surgical 
and cancer patients
(1)
.Carbapenem (imipenem/cilastatin and meropenem) drugs are beta-
lactam type antibiotics with a broad spectrum of activity and coverage of Gram-positive and 
Gram-negative aerobic and anaerobic bacteria.Imipenem/cilastatin and meropenemuse have 
increased as a result of high resistant rates to other antibiotics
(2)
. 
Like other broad spectrum antibiotics, carbapenems are prescribed as a part of empiric 
therapy in most serious hospitalised infections. Imipenem is a semisynthetic carbapenem co-
administrated with cilastatin, to prevent renal metabolism of imipenem by dehydropeptidase Ι 
(DHP Ι). In contrast, this co-administration with the renal dehydropeptidase inhibitor, 
cilastatin is not necessarywith meropenem, because this agent is not hydrolyzed by DHP Ι(1). 
The incidence of imipenem/cilastatin and meropenem resistance is increasing. One of the 
reasons could be the overuse of these broad spectrum antibiotics in hospitalized patients 
including Intensive Care Units (ICUs)
(3)
. Improving the ICU environment involves education 
of critical care staff regarding the rational use of these drugs
(1)
. According to a study 
conducted in in Sana'a, Yemen by alyahawi et al. 2018
(4)
, the resistant rate 
 ofmeropenembased on culture results was seen in 25.3% of all collected isolates.In this study, 
we reviewed the utilization of these antibiotics in critically ill patients. 
2. Methods:  
The study was performed in ICU at a private hospital in Sana’a, Yemen. All the patients on 
carbapenem drugsfrom September, 2018 to March, 2019 were included. A total of 80 of the 
patientson carbapenem drugs were collected from ICU at the mentioned study period.The 
study protocol was approved by the institutional ethical committee. The data was analyzed in 
order to identify dosage adjustment accordingGFR stages, carbapenem selection according to 
culture results or empirical therapy, major and moderate drug-drug interactions according to 
Drugs.com and Medscape.com, andantibiotic use in combination with carbapenem. Full 
ethical clearance was obtained from the qualified authorities who approved the study 
design.Statistical analysis included usage of Chi-square testsusing the software package SPSS 
21.0. 
3. Results: 
Total of 80 patients at ICU were evaluated. The results of the study showedthat 78.8% of the 
study sample were men and 21.3% were women. Also 43.8 of the study sample were aged >= 
60 years old. In the present study, 80% of the patients were onmeropenem and 20% of total 
patients on imipenem drug. According to the glomerular filtration rate (GFR) classification, 
43.8% of patients had chronic kidney diseases (CKD) stage 3. 
Table 1. Distribution of the study variables  
Variable Frequency % 
Gender M 63 78.8% 
F 17 21.3% 
 
Age group 
0-19 4 5% 
20-39 21 26.3% 
40-59 20 25% 
>=60 35 43.8% 
Imipenem 16 20% 
Meropenem 64 80% 
 
 
CKD Stage 
1 12 15.0 % 
2 11 13.8% 
3 35 43.8% 
4 19 23.8% 
5 3 3.8% 
 
 
Figure 1. Distribution of age groups among the study sample 
 From the study findings, 36 of patients with chest infection (45%) were 
onimipenem/cilastatinor meropenem, followed by patients with sepsis (25%). 
Table 2. Distribution of Carbapenem drugs used according to Diagnosis 
 
 
Variable 
Carbapenem used  
Total 
Imipenem/cilastatin Meropenem 
 
 
 
 
Diagnosis 
 
Brain Infection 1 2 3 
Chest Infection 9 27 36 (45%) 
CSF Infection 0 1 1 
Head Infection 0 1 1 
Meningitis 1 6 7 
Osteomyelitis 0 5 5 
SBP 0 1 1 
Sepsis 2 18 20 (25%) 
UTI 3 3 6 
Total 16 64 80 
According to glomerular filiation rate, there was 36.3% of carbapenem drugs 
(imipenem/cilastatin or meropenem) were needed dosage adjustment according to GFR 
stages. In addition, one carbapenem drug is not recommended by evidence used for 
patient. However, 8.8% of carbapenem drugs were used in low doses (table 3). 
 
 
 
 
 
 
Table3.Dosage Adjustment according to GFR stages 
Variable Frequency % 
Need dosage adjustment 29 36.3% 
Not need dosage 
adjustment 
43 53.8% 
Low dose 7 8.8% 
Not recommended 1 1.3% 
Total 80 100.0 
 
  
Figure2. Dosage adjustment according to GFR Stages 
 
Table 4 showed the frequency of moderate drug-drug interactions in the present 
study.According to the drugs.com and Medscape, the frequency of moderate drug-drug 
interactions between all the patients' drugs was observed in 11types. Detailed comments were 
reported in table 4. 
 
 
 
 
 
 
 
 
Table4. Moderate Drug-Drug Interaction 
Type of Drug-drug 
interaction 
Frequency Comments 
Aspirin-Clopidogrel 3 Increase the bleeding. 
Aspirin-Heparin 
 
 
 
1 
The coadministration of nonsteroidal anti-
inflammatory drugs (NSAIDs) and heparin or low 
molecular weight heparin (LMWH) may potentiate 
the risk of bleeding. NSAIDs interfere with platelet 
adhesion and aggregation and may prolong bleeding 
time in healthy individuals.  
Azithromycin-
Simvastatin 
 
1 
Macrolide antibiotics that inhibit CYP450 3A4 may 
significantly increase the plasma concentrations of 
HMG-CoA reductase inhibitors. 
 Captopril-Heparin 
 
 
 
 
1 
The concomitant use of angiotensin converting 
enzyme (ACE) inhibitors or angiotensin receptor 
blockers (ARBs) and heparin or low molecular 
weight heparins may increase the risk of 
hyperkalemia. ACE inhibitors, ARBs, and some 
heparins individually have been associated with 
increased potassium levels or hyperkalemia. 
Ceftriaxone-Warfarin 
 
 
1 
Prothrombin time and INR should be monitored and 
the patient closely observed for signs of bleeding. 
The anticoagulant dose may be adjusted as indicated. 
Metronidazole-
Phenytoin 
 
 
 
2 
Coadministration with a metronidazole may increase 
the serum concentrations of phenytoin. The 
interaction has been reported with metronidazole, 
and the proposed mechanism is inhibition of 
phenytoin metabolism via CYP450 2C9. 
Phenytoin-Insulin 
 
 
 
1 
Caution is advised when drugs that can interfere 
with glucose metabolism are prescribed to patients 
with diabetes. Close clinical monitoring of glycemic 
control is recommended following initiation or 
discontinuation of these drugs, and the dosages of 
concomitant antidiabetic agents adjusted as 
necessary. 
Phenytoin-Nifedipine 
 
 
 
1 
Nifedipine may increase plasma phenytoin levels. 
Toxicity has been reported. The proposed 
mechanism is inhibition of CYP450 3A4 
metabolism. In addition, phenytoin may significantly 
decrease calcium channel blocker (CCB) serum 
levels by inducing first-pass metabolism and the 
systemic clearance. 
 
The frequency of major drug-drug interactionswas demonstrated in table 5.According to the 
drugs.com and Medscape, the frequency of major drug-drug interactions between all the 
patients' drugs was observed in three patients. Detailed major drug-drug interactions were 
reported in table 5. 
Table5.Major Drug-Drug Interactions 
Type of Drug-drug 
interaction 
Frequency Comments 
Amlodipine-Simvastatin 
 
 
 
 
1 
Coadministration with amlodipine may 
significantly increase the plasma 
concentrations of simvastatin and its active 
metabolite, simvastatin acid, and potentiate 
the risk of statin-induced myopathy. The 
proposed mechanism is amlodipine inhibition 
of simvastatin metabolism via intestinal and 
hepatic CYP450 3A4. 
 Tramadol-Imipenem 
 
 
1 
The risk of seizures may be increased during 
coadministration of tramadol with any 
substance that can reduce the seizure 
threshold, such as carbapenems.These agents 
are often individually epileptogenic and may 
have additive effects when combined.  
Tramadol-Meropenem 
 
 
1 
The risk of seizures may be increased during 
coadministration of tramadol with any 
substance that can reduce the seizure 
threshold, such as carbapenems.These agents 
are often individually epileptogenic and may 
have additive effects when combined.  
 
In this study, there were 91.3% of patients on carbapenem drugs as empirical therapy (P < 
0.001) However, 8.8% of patients used carbapenem drugs according to culture results. 
 
Table6.Carbapenem Selection according to culture or empirical therapy 
Variable Frequency Percent 
Empirical Therapy 73 91.3% 
According to culture results 7 8.8% 
Total 80 100.0 
 
Figure3. Distribution of carbapenem selection according to culture results or empirical 
therapy 
 
Figure 4 showed the percentage of antibiotics used before carbapenem administration for the 
study sample. Carbapenem drugs were administered in 75% of the patients as the first line. In 
contrast, 25% of patients used other antibiotics before carbapenemadminstration. 
  
 
Figure4.Antibiotics used before carbapenemdrug 
 
The review of the patients'drugsshowed different drugs related problems. According to the 
study findings, the frequency of therapeutics duplication with carbapenem drugs was in 41 
(51.3%) of patients. Moreover, the therapeutic duplication of ceftriaxone with carbapenem 
drugs was in 38(92.7%) of these patients. In addition, one patient with urinary tract infection 
(UTI) was on moxifloxacin drug (less effective for UTI). Carbapenem drugs have a broad 
spectrum of activity, so most other antibiotics are unnecessaryas combination to 
carbapenemdrugs (table 7). 
 
Table 7. Distribution of Other Antibiotics Use in Combination with Carbapenem according 
to Diagnosis 
 
Type of Antibiotic 
Chest 
Infection 
Head 
Infection 
Meningitis Osteomyelitis Sepsis UTI 
Amoxicillin-Clavulanic Acid 1 D 0  0  0  0  0  
Azithromycin 1  0  0  0  0  0  
Cefepime 0  0  0  0  1 D 0  
Ceftriaxone 8 D 0  3 D 0  6 D 1 D 
Cefuroxime 1 D 0  0  0  0  0  
Ciprofloxacin 1  0  0  0  0  0  
Doxyxcycline-Ceftriaxone 0  0  0  0  1 D 0  
Levofloxacin 1  0  0  0  0  0  
Levofloxacin-Metronidazole 1  0  0  0  0  0  
Linezolid 0  0  0  0  1  0  
Metronidazole 2  0  1  2  2  1  
Metronidazole-Ceftriaxone 4 D 0  1 D 1 D 2 D 1 D 
Metronidazole-Ciprofloxacin 1  0  0  0  0  0  
Metronidazole-Moxifloxacin 0  0  0  1  0  0  
Moxifloxacin 3  0  0  0  3  1 N 
Moxifloxacin-Ceftriaxone 8 D 0  0  0  2 D 0  
Moxifloxacin-Metronidazole 0  0  0  0  1  0  
Vancomycin 1  1  1  0  0  0  
Vancomycin-Ampicillin 0  0  1 D 0  0  0  
Vancomycin-Ceftriaxone 0  0  1 D 0  0  0  
Vancomycin-Levofloxacin 0  0  0  1  0  0  
D: Therapeutic Duplication; N: Not Recommended 
  
4. Discussion:  
Applying standard treatment guidelineswith training and supervision may be helpful in 
guiding physicians in the appropriate use of carbapenem drugs in hospital. 
Generally, most physicians used carbapenem drugs empirically for patients admitted to the 
ICU without the identification the exact infection. They might think that all patients admitted 
to ICU have a severe infection (5).  
Continuous drugs education by therapeutic committee and regular drug utilization evaluation 
programs could help in the rational medication use. The various clinical conditions and 
severity of infection for patient in ICU need the use of drugs from different classes
(6)
. 
The results of this study revealed that the majority of patients (43.8%) received carbapenem 
drugs were equal or above 60 years old. Similarly, a study conducted to evaluation of 
meropenem utilization in intensive care unit in Sudan by Sanhoury et al.,
(5)
 which found 
majority of patient, above 60 years old, received meropenem drug. 
In the current study, 91.3% of carbapenemdrugs were prescribed without culture results; 
which means that these drugswereprescribed depending on physician' experience or on the 
severity of infection, but not according to isolated bacteria. This was not in agreement with a 
study conducted to evaluate the use of carbapenem in a French University hospital by Jary et 
al., which found 60% of meropenem was prescribed empirically 
(7)
. 
The irrational utilization of broad-spectrum antibiotics such as carbapenem drugs can lead to 
the development of several resistant strains of microbes. These attribute significantly towards 
increase in the costs of health care and patient morbidity and mortality
(8)
. So, monitoring and 
evaluation of antimicrobial agents are one of the recommended strategies to prevent, control 
resistance, and to improve the rational use of these drugs
(5)
.  
The high prevalence of resistance in intensive care units (ICUs) is a key factor to increase the 
severity of illness of the patients, prolonged hospital stays, and the increase use of broad 
spectrum antibiotics.The choice of antimicrobial therapy for nosocomial infections is often 
governed by hospital resistance patterns and surveillance of bacterial susceptibility. This 
canassist in clinical decisions regarding empirical antimicrobial therapy at each hospital
(9)
. 
The demand for the increased use of antibiotics such as carbapenem drugs as well as 
noncompliance with infectious disease guidelines both contribute to the rise of bacterial 
resistance. In United States,20% of resistance rates were reported to imipenem/cilastatin. It 
was frequently usedfor infection of high suspectedP. aeruginosa
(10)
. 
The choice of appropriate dose of imipenem/cilastatin should be based on the location and 
severity of the infection, the susceptibility of the isolated pathogen(s), and the renal function 
of the patient. Adult patients with impaired renal function, as defined by creatinine clearance 
(CrCl) <70 mL/min/1.73 m
2
, require dosage adjustment
(11)
. 
According to our study results, there was 36.3% of carbapenem drugs 
(imipenem/cilastatinandmeropenem) were required dosage adjustment according to GFR 
stages. 
This is similar to the results by a study conducted in Iran by Shiva et al.
(12)
, which found that 
the dosage of imipenem was inappropriate in 36% of patients, and the dosage adjustment 
(when needed) was either not done or done inappropriately in 64.3% of patients. 
Shiva et al.,also evaluated the utilization of imipenem/cilastatin in an educational hospital in 
Iran and found that there was a high empirical prescription of imipenem/cilastatin without 
considering culture and antimicrobial susceptibility results, and they observed there was a 
lack of attention to dosage adjustments in patients with renal insufficiency. Furthermore, in 
another study conducted by Sakhaiyan et al. 
(13)
,reported that the dosage adjustment of 
imipenem/cilastatin was not prescribed appropriately at their institution, and the researchers 
concluded that there was a need to more education for the health care professionals regarding 
 the carbapenem dosage adjustment and their adjustment depends on the weight and the renal 
function of the patient. Central nervous system (CNS) disorders and renal insufficiency were 
risk factors for seizure occurrence. Therefore, the patients who received imipenem/cilastatin 
at higher than recommended doses had an increased risk of seizures, especially in patients 
with renal insufficiency
(14)
. 
Some studies found that the high consumption of carbapenems drugs was attributed for the 
prevalence of Carbapenem-resistant Gram-negative bacterial pathogens
(15)
. 
In March 2017, the National Health and Family Planning Commission (NHFPC) launched a 
special stewardship in the clinical use of carbapenems
(16)
. 
According to the evaluation of drug-drug interactions in the present study, the major drug-
drug interactions between all the patients' drugs were observed in three patients (table 5). 
Coadministration with amlodipine may significantly increase the plasma concentrations of 
simvastatin and its active metabolite, simvastatin acid, and potentiate the risk of statin-
induced myopathy. The proposed mechanism is amlodipine inhibition of simvastatin 
metabolism via intestinal and hepatic CYP450 3A4.Limit simvastatin dose to no more than 
20 mg/day when used concurrently.In addition, the risk of seizures may be increased during 
coadministration of tramadol with any substance that can reduce the seizure threshold, such 
as carbapenems (imipenem/cilastatin or meropenem). These agents are often individually 
epileptogenic and may have additive effects when combined
(17, 18)
. 
The evaluation of patients' drugs showedthe frequency of therapeutics duplication with 
carbapenemdrugs (beta-lactam antibiotics) was in 41 (51.3%) of patients. In addition, the 
therapeuticduplication of ceftriaxone with carbapenem drugs was seen in 38 (92.7%) of these 
patients.Furthermore, carbapenem drugs have a broad spectrum of activity, so most other 
antibiotics are unnecessary as combination to carbapenem drugs such as levofloxacin and 
moxifloxacin. 
In this study, one patient with urinary tract infection (UTI) was on moxifloxacin drug. 
Not all fluoroquinolones can be used for urinary tract infections based on their 
pharmacokinetic profiles. Moxifloxacin achieve considerably lower concentrationsin the 
urine than other quinolones and are notapproved for this indication
(19)
. 
In the current study, carbapenem drugs were administered in 75% of the patients as the first 
line. Interestingly, the prior use of antibiotics with broad-spectrum coverage, such as 
carbapenem drugs, was significantly associated with the acquisition of resistance
(20)
. 
Carbapenemdrugs should be reserved for the treatment of infections due to MDR 
pathogens
(21)
. 
Conclusion: The study resultsshowed that empiric therapy was prescribed in most cases 
(91.25%).In addition, about 36.3% of the patients required dosage adjustment according to 
GFR stages. Dosage adjustment, however, was not done as appropriate, mainly in patients 
who did not have a stable GFR. The need for interventional actions on carbapenems use is 
essential in the various units of the hospital.In the present study, the frequency of therapeutic 
duplication and drug-drug interactions were observed.More stringent controls and the 
implementation of stewardship principles are necessary to reduce the inappropriate use of 
carbapenem drugs. 
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